Decode Shares Rise on Prostate Cancer Findings | GenomeWeb

NEW YORK (GenomeWeb News) – Decode Genetics shares were up nearly 11 percent in mid-afternoon trading to $.61 each, following the company's publication yesterday in the advance, online edition of Nature Genetics, reporting that it has identified four new genetic variants associated with prostate cancer risk.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.